893411-52-4

Usage

Uses

Used in Pharmaceutical Industry:
Spiro[2.5]octan-5,7-dione is used as a key intermediate in the synthesis of pharmaceuticals for its unique structure and reactivity, contributing to the development of new drugs with potential therapeutic benefits.
Used in Agrochemical Industry:
In the agrochemical sector, spiro[2.5]octan-5,7-dione serves as a building block in the production of agrochemicals, enabling the creation of effective compounds for crop protection and pest control.
Used in Dye Industry:
Spiro[2.5]octan-5,7-dione is utilized as a precursor in the synthesis of dyes, leveraging its unique structural properties to produce a variety of colorants for different applications.
Used in Organic Synthesis:
As a versatile building block, spiro[2.5]octan-5,7-dione is used in organic synthesis for the construction of complex molecules, facilitating the development of novel chemical entities with diverse applications.
Used in Material Science:
Due to its unique spirocyclic structure, spiro[2.5]octan-5,7-dione has potential applications in material science, where it can be employed to develop new materials with specific properties for various uses.
Used in Polymer Chemistry:
Spiro[2.5]octan-5,7-dione also finds use in polymer chemistry, where its structural properties can be harnessed to design and synthesize new polymers with tailored characteristics for specialized applications.

Upstream product

• 1554535-00-0 (1-methoxycarbonylmethyl-cyclopropyl)-acetic acid 
• 1554535-02-2 (1-chlorocarbonylmethyl-cyclopropyl)-acetic acid methyl ester 
• 1554535-07-7 [1-(2-oxo-propyl)-cyclopropyl]-acetic acid 
• 70197-77-2 (1-carboxymethylcyclopropyl)acetic acid 
• 144728-22-3 6-oxa-spiro[2.5]octane-5,7-dione 
• 74592-36-2 ethyl cyclopropenylideneacetate 
• 1554535-08-8 {1-[(methoxy-methyl-carbamoyl)-methyl]-cyclopropyl}-acetic acid 
• 1554535-04-4 [1-(2-oxo-propyl)-cyclopropyl]-acetic acid methyl ester 
• 20778-47-6 (1-cyanomethyl-cyclopropyl)-acetonitrile 
• 62266-37-9 cyclopropylidenepropanone 
• 108-59-8 malonic acid dimethyl ester 

Downstream Products

• 893412-58-3 4'-cyclohexyl-2'-cyclopentyl-3'-[4-(trifluoromethyl)benzoyl]-4',8'-dihydro-1'H-spiro[cyclopropan-1,7'-quinolin]-5'(6'H)-one 
• 1355249-20-5 C₁₇H₁₈N₂O₂ 
• 1355249-21-6 C₁₇H₁₇BrN₂O₂ 
• 1383718-73-7 2'-((4-chlorophenyl)amino)-6',8'-dihydro-5'H-spiro[cyclopropane-1,7'-quinazolin]-5'-one 

Relevant academic research and scientific papers

BICYCLIC IMIDAZOLE DERIVATIES USEFUL FOR THE TREATMENT OF RENAL DISEASE, CARDIOVASCULAR DISEASES AND FIBROTIC DISORDERS

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

NOVEL PROCESS FOR PREPARATION OF SPIRO[2.5]OCTANE-5,7-DIONE AND SPIRO[3.5]NONANE-6,8-DIONE

This invention relates to methods for the synthesis of spiro[2.5]octane-5, 7-dione and spiro[3.5]nonane-6, 8-dione which are useful as intermediates in the manufacture of pharmaceutically active ingredients.

Short and tandem syntheses of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione via diethyl acetonedicarboxylate

A general synthetic route to spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione that involves cyclization of the related acrylates and diethyl acetonedicarboxylate, followed by decarboxylation, has been developed. Compared with previous synthetic methods, the developed protocol avoids the use of column chromatography in each of the synthetic steps. Therefore, it can be readily scaled-up. The use of diethyl acetonedicarboxylate under mild conditions to build the skeleton of 1,3-cyclohexanedione has proved to be very efficient.

Process for preparing spiro[2.5]octane-5,7-dione

Disclosed is a method for the synthesis of spiro[2.5]octane-5,7-dione useful as intermediate in the manufacture of pharmaceutically active ingredients. Also disclosed are novel intermediates used in the synthesis of this compound.

PROCESS FOR PREPARING SPIRO[2.5]OCTANE-5,7-DIONE

Disclosed is a method for the synthesis of spiro[2.5]octane-5,7-dione useful as intermediate in the manufacture of pharmaceutically active ingredients. Also disclosed are novel intermediates used in the synthesis of this compound.

METABOTROPIC GLUTAMATE RECEPTOR MODULATORS

The invention relates to heterocyclic derivatives of formula (I) as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders wherein Y, W, R1, R2 and R3 are as defined in claim 1.

METABOTROPIC GLUTAMATE RECEPTOR MODULATORS

The invention relates to heterocyclic derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorder

(5S) -3-[(S)-FLUORO (4-TRIFLUOROMETHYLPHENYL) METHYL]-5,6,7,8-TETRAHYDROQUINOLINE-5-OL DERIVATIVES AND USE THEREOF AS CETP INHIBITORS

The invention relates to novel tetrahydroquinoline derivatives of formula (I), wherein R1 represents cyclohexyl or cyclopentyl, R2 and R3 each represent methyl or jointly form a cyclobutane, and R4 represents cyclopentyl or isopropyl, the salts and solvates thereof, and the solvates of said salts. Also disclosed are a method for the production thereof, the use thereof on its own or in combinations for the treatment and/or prevention of diseases, and the use thereof for producing medicaments, particularly as a cholesterol ester transfer protein (CETP) inhibitor in order to treat and/or prevent cardiovascular diseases, especially hypolipoproteinemia, dyslipidemia, hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, and arteriosclerosis.